This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 13 print issues and online access
$259.00 per year
only $19.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
19 March 2025
A Correction to this paper has been published: https://doi.org/10.1038/s41386-025-02087-2
References
Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M. Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995;152:626–8.
Difede J, Rothbaum BO, Rizzo AA, Wyka K, Spielman L, Reist C, et al. Enhancing exposure therapy for posttraumatic stress disorder: virtual reality and imaginal exposure with a cognitive enhancer: a randomized clinical trial. Transl Psychiatry. 2022;12:1–9.
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Zimand E, Hodges L, et al. Facilitation of psychotherapy with D-cycloserine, a putative cognitive enhancer. Arch Gen Psychiatry. 2004;61:1136–44.
Yang YJD, Allen T, Abdullahi SM, Pelphrey KA, Volkmar FR, Chapman SB. Neural mechanisms of behavioral change in young adults with high-functioning autism receiving virtual reality social cognition training: a pilot study. Autism Res. 2018;11:713–25.
van ’t Wout-Frank M, Arulpragasam AR, Faucher C, Aiken E, Shea MT, Jones RN, et al. Virtual reality and transcranial direct current stimulation for posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2024;81:437–46.
Kaplan AD, Cruit J, Endsley M, Beers SM, Sawyer BD, Hancock PA. The effects of virtual reality, augmented reality, and mixed reality as training enhancement methods: a meta-analysis. Hum Factors. 2021;63:706–26.
Author information
Authors and Affiliations
Contributions
Dr. Barbara Rothbaum wrote the first draft of the article and edited the final draft. Dr. Jacob Rothbaum wrote the second draft of the article and formatted it for publication.
Corresponding author
Ethics declarations
Competing interests
Dr. Barbara Rothbaum has received Research/Grants from Wounded Warrior Project, NIH, Department of Defense, NSF, Bob Woodruff Foundation, MAPS; is a stockholder in Virtually Better; has been paid as a consultant by Otsuka, Psychwire, Senseye, MAPS, Jazz Pharmaceuticals, GoodCap, Transcend, Penumbra; serves on the Scientific Advisory Boards for Anxiety and Depression Association of America (ADAA), National Center for PTSD; serves on the Board of Directors for GratitudeAmerica; receives Royalties from Oxford University Press, APPI, Emory University. Emory Healthcare Veterans Program is supported by a grant from the Wounded Warrior Project. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Dr. Jacob Rothbaum reports no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rothbaum, B.O., Rothbaum, J.O. Virtual reality exposure therapy advances and potential for clinical and experimental use. Neuropsychopharmacol. 50, 343–344 (2025). https://doi.org/10.1038/s41386-024-01930-2
Published:
Issue date:
DOI: https://doi.org/10.1038/s41386-024-01930-2